stockportfolio.pro
Stocks / PODD vs RGC
PODD vs RGC
Insulet Corporation and Regencell Bioscience Holdings Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
PODD is the larger company ($9.9B vs $9.3B). On the fundamentals, PODD has the stronger return on equity (16.3% vs -52.3%). Full numbers below — the stronger figure on each row is in green.
| Insulet Corporation (PODD) | Regencell Bioscience Holdings Limited (RGC) | |
|---|---|---|
| Market cap | $9.9B | $9.3B |
| Revenue (latest FY) | $2.71B | $0 |
| Net income (latest FY) | $247.10M | $-4.30M |
| Revenue growth (5y CAGR) | 24.5% | — |
| Net margin | 9.1% | — |
| Return on equity | 16.3% | -52.3% |
| P/E ratio | 33.5 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 8 | 0 |
| Positive free cash flow | Yes | No |
Compare with another company:
See the full PODD vs RGC breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open PODD's full financials → Open RGC's full financials →More comparisons
Frequently asked questions
Which is bigger, PODD or RGC?
Insulet Corporation is larger by market capitalization — $9.9B versus $9.3B.
Which grows faster, PODD or RGC?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.